COVID-19: Expert committee recommends restricted emergency use of SII, Bharat Biotech s vaccines ANI | Updated: Jan 02, 2021 21:51 IST
New Delhi [India], January 2 (ANI): The Subject Expert Committee (SEC) of Central Drugs Standards Control Organisation on Saturday made recommendations to the Drugs Controller General of India to grant permission for restricted emergency use of SII, Bharat Biotech s vaccines.
As per an official release, the SEC met on Friday and Saturday and made its recommendations in respect of accelerated approval process request of Serum Institute of India (SII), Bharat Biotech International Ltd as well as about phase-III trials of Cadila Healthcare Ltd. Grant of permission for restricted emergency use of the vaccine, subject to multiple regulatory conditionalities, to Serum Institute of India, Pune, it said.
With 19,078 new COVID-19 cases, India s tally reaches 1,03,05,788 ANI | Updated: Jan 02, 2021 23:26 IST
New Delhi [India], January 2 (ANI): India reported 19,078 new COVID-19 cases in the last 24 hours, taking the total number of positive cases in the country to 1,03,05,788, the Ministry of Health and Family Welfare (MoHFW) informed on Saturday.
The total number of active cases now stands at 2,50,183. As many as 224 people succumbed to coronavirus in the last 24 hours and the death toll has mounted to 1,49,218.
So far 99,06,387 recoveries have been reported in the country.
As many as 8,29,964 samples tested for the coronavirus on Friday and the count of samples tested so far has reached 17,39,41,658, the Indian Council of Medical Research (ICMR) informed.
India may need 1.3 lakh-1.4 lakh Covid vaccination centres: Study
Premium
(AP)
Share Via
Read Full Story
New Delhi: For Covid-19 vaccination, India may need 1.3 lakh-1.4 lakh vaccination centres, 1 lakh healthcare professionals as inoculators and 2 lakh support staff or volunteers to support government’s mass-inoculation program, a FICCI-EY knowledge paper has indicated.
The paper on private healthcare players to augment government’s capacity across the value chain of vaccine distribution and administration also highlighted that 81% of survey respondents from private healthcare industry are willing to inoculate frontline workers in local areas and 75% are willing to inoculate their local communities,70% are willing to allocate manpower in semi-urban/rural areas for vaccination and 94% are willing to impart training for inoculation.
How India plans to ensure safety and efficacy of covid-19 vaccines
The meeting of the subject expert committee of Central Drugs Standards Control Organisation has asked Bharat Biotech International and Serum Institute of India for more data on the safety and efficacy of their shots.Premium
3 min read
Share Via
Read Full Story
NEW DELHI: Safety and efficacy are the primary concerns of the government while granting emergency use authorization (EUA) to any covid-19 vaccine in the country.
The government s cautious approach before approving a vaccine is apparent. The meeting of the subject expert committee of Central Drugs Standards Control Organisation on Wednesday asked Bharat Biotech International and Serum Institute of India for more data on the safety and efficacy of their shots and deferred recommending them for emergency use.
The health minister was digitally addressing the Inter-Ministerial meeting on Vaccination of South Asia against covid-19 by the World Bank on Thursday.Pune-based SII is in a process to manufacture Covishield which undergoing phase 3 stage of the clinical trials